Recombinant factor VIIa in trauma patients with the 'triad of death'.

摘要: A B S T R C Introduction: The use of recombinant factor VIIa (rFVIIa) in trauma patients is usually part rescue therapy when haemorrhage and coagulopathy have not responded to conventional treatment. In this scenario, are likely one or more components the 'triad death' (coagulopathy, acidosis hypothermia). aim study was report on outcome with immediately prior receiving rFVIIa. Materials methods: Trauma rFVIIa were identified from Australia New Zealand Haemostasis Registry (ANZHR) included study. defined as an INR >1.5, serum pH <7.2 a core temperature <35 8C. Pre-dose clinical signs, investigations, adverse events outcomes analysed. Results: There 2792 ANZHR, which 386 45 had death'. Patients significantly older higher injury severity scores than other patients, mortality 68.9%. Survivors less acidaemic (p < 0.001) packed red blood cell (PRBC) transfusion administration = 0.041) non-survivors triad death. Discussion: face refractory bleeding, coagulopathy, hypothermia following resuscitation, associated survival 31% may be considered management option. Administration <6.91 appears futile.